Federal Pharmaceuticals (03933) rose more than 5%. As of press release, it rose 5.2% to HK$9.92, with a turnover of HK$18.378 million.
The Zhitong Finance App learned that Federal Pharmaceuticals (03933) rose by more than 5%. As of press release, it had risen 5.2% to HK$9.92, with a turnover of HK$18.378 million.
According to the news, CDE's official website recently announced that the clinical trial application for Novo Nordisk's Class 1 new drug amycretin tablets has been accepted. According to reports, this is a long-acting oral co-agonist of GLP-1 receptor and amylin receptor developed by Novo Nordisk, and is a next-generation weight loss therapy. In a small phase 1 clinical study recently announced by Novo Nordisk, patients lost 13.1% of their body weight after 12 weeks of treatment with this product (1.1% vs. placebo group).
According to a recent research report by Zhongtai Securities, the company has achieved full coverage in the field of diabetes, and GLP-1 achieved significant progress in 2023:1) Liraglutide injection was reported; 2) the diabetes indication for simeglutide injection completed phase III clinical enrollment, and its weight loss indications were approved; 3) GLP-1/GCG/GIP three-target gastrointestinal hormones have been clinically approved for diabetes, weight loss, NASH, etc.; at the same time, second-generation gastrointestinal hormones have also been approved for clinical use in the US; at the same time, second-generation gastrointestinal hormones are also being actively promoted.